• Something wrong with this record ?

Convexity Meningiomas in Patients with Neurofibromatosis Type 2: Long-Term Outcomes After Gamma Knife Radiosurgery

H. Ruiz-Garcia, DM. Trifiletti, N. Mohammed, YC. Hung, Z. Xu, T. Chytka, R. Liscak, M. Tripathi, D. Arsanious, CP. Cifarelli, MP. Caceres, D. Mathieu, H. Speckter, GP. Lekovic, GU. Mehta, JP. Sheehan

. 2021 ; 146 (-) : e678-e684. [pub] 20201103

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21026163

Grant support
U54 GM104942 NIGMS NIH HHS - United States

BACKGROUND: Convexity meningiomas are common tumors requiring treatment in patients with neurofibromatosis type 2 (NF2). Although different therapeutic options are described for sporadic convexity meningioma, much less is known about these lesions in patients with NF2 despite their distinct biology and need for multiple treatments. We analyzed the value of Gamma Knife radiosurgery (GKRS) as definitive treatment for convexity meningiomas in patients with NF2. METHODS: This international multicenter retrospective study was approved by the International Radiosurgery Research Foundation. Patients with NF2 with at least 1 convexity meningioma and 6-month follow-up after primary GKRS were included. RESULTS: Inclusion criteria were met by 18 patients with NF2. A total of 120 convexity meningiomas (median treatment volume, 0.66 cm3 [range, 0.10-21.20 cm3]) were analyzed. Median follow-up after initial GKRS was 15.6 years (range, 0.6-25.5 years). Median age at GKRS was 32.5 years (range, 16-53 years). Median number of meningiomas per patient was 13 (range, 1-27), and median number of convexity lesions receiving GKRS per patient was 3.5 (range, 1-27). One case of tumor progression was reported 24 years after GKRS, leading to actuarial progression-free survival rates of 100% at 2, 5, and 10 years. No malignant transformation or death due to meningioma or radiosurgery was recorded. CONCLUSIONS: GKRS is safe and effective as definitive treatment of small to medium-sized convexity meningiomas in patients with NF2. Despite concerns about the particular mutational burden of these tumors, no malignant transformation manifested after treatment. GKRS represents a minimally invasive option that offers long-term tumor control to this specific group of patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026163
003      
CZ-PrNML
005      
20211026133145.0
007      
ta
008      
211013s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.wneu.2020.10.153 $2 doi
035    __
$a (PubMed)33152493
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ruiz-Garcia, Henry $u Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA; Department of Neurological Surgery, Mayo Clinic, Jacksonville, Florida, USA
245    10
$a Convexity Meningiomas in Patients with Neurofibromatosis Type 2: Long-Term Outcomes After Gamma Knife Radiosurgery / $c H. Ruiz-Garcia, DM. Trifiletti, N. Mohammed, YC. Hung, Z. Xu, T. Chytka, R. Liscak, M. Tripathi, D. Arsanious, CP. Cifarelli, MP. Caceres, D. Mathieu, H. Speckter, GP. Lekovic, GU. Mehta, JP. Sheehan
520    9_
$a BACKGROUND: Convexity meningiomas are common tumors requiring treatment in patients with neurofibromatosis type 2 (NF2). Although different therapeutic options are described for sporadic convexity meningioma, much less is known about these lesions in patients with NF2 despite their distinct biology and need for multiple treatments. We analyzed the value of Gamma Knife radiosurgery (GKRS) as definitive treatment for convexity meningiomas in patients with NF2. METHODS: This international multicenter retrospective study was approved by the International Radiosurgery Research Foundation. Patients with NF2 with at least 1 convexity meningioma and 6-month follow-up after primary GKRS were included. RESULTS: Inclusion criteria were met by 18 patients with NF2. A total of 120 convexity meningiomas (median treatment volume, 0.66 cm3 [range, 0.10-21.20 cm3]) were analyzed. Median follow-up after initial GKRS was 15.6 years (range, 0.6-25.5 years). Median age at GKRS was 32.5 years (range, 16-53 years). Median number of meningiomas per patient was 13 (range, 1-27), and median number of convexity lesions receiving GKRS per patient was 3.5 (range, 1-27). One case of tumor progression was reported 24 years after GKRS, leading to actuarial progression-free survival rates of 100% at 2, 5, and 10 years. No malignant transformation or death due to meningioma or radiosurgery was recorded. CONCLUSIONS: GKRS is safe and effective as definitive treatment of small to medium-sized convexity meningiomas in patients with NF2. Despite concerns about the particular mutational burden of these tumors, no malignant transformation manifested after treatment. GKRS represents a minimally invasive option that offers long-term tumor control to this specific group of patients.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a edém mozku $x etiologie $7 D001929
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a meningeální nádory $x komplikace $x patologie $x radioterapie $7 D008577
650    _2
$a meningeom $x komplikace $x patologie $x radioterapie $7 D008579
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetné primární nádory $x komplikace $x radioterapie $7 D009378
650    _2
$a neurofibromatóza 2 $x komplikace $7 D016518
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a radiochirurgie $x škodlivé účinky $x metody $7 D016634
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
650    _2
$a tumor burden $7 D047368
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Trifiletti, Daniel M $u Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA; Department of Neurological Surgery, Mayo Clinic, Jacksonville, Florida, USA
700    1_
$a Mohammed, Nasser $u Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia, USA
700    1_
$a Hung, Yi-Chieh $u Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia, USA
700    1_
$a Xu, Zhiyuan $u Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia, USA
700    1_
$a Chytka, Tomas $u Department of Neurological Surgery, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Liscak, Roman $u Department of Neurological Surgery, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Tripathi, Manjul $u Post Graduate Institute of Medical Education and Research, Chandigarh, India
700    1_
$a Arsanious, David $u Department of Neurological Surgery, West Virginia University, Morgantown, Virginia, USA
700    1_
$a Cifarelli, Christopher P $u Department of Neurological Surgery, West Virginia University, Morgantown, Virginia, USA
700    1_
$a Caceres, Marco Perez $u Department of Neurological Surgery, Centre de recherche du CHUS, Université de Sherbrooke, Sherbrooke, Quebec, Canada
700    1_
$a Mathieu, David $u Department of Neurological Surgery, Centre de recherche du CHUS, Université de Sherbrooke, Sherbrooke, Quebec, Canada
700    1_
$a Speckter, Herwin $u Dominican Gamma Knife Center and CEDIMAT Hospital, Santo Domingo, Dominican Republic
700    1_
$a Lekovic, Gregory P $u House Ear Institute, Los Angeles, California, USA
700    1_
$a Mehta, Gautam U $u House Ear Institute, Los Angeles, California, USA
700    1_
$a Sheehan, Jason P $u Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia, USA. Electronic address: jsheehan@virginia.edu
773    0_
$w MED00167613 $t World neurosurgery $x 1878-8769 $g Roč. 146, č. - (2021), s. e678-e684
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33152493 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133152 $b ABA008
999    __
$a ok $b bmc $g 1715006 $s 1146670
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 146 $c - $d e678-e684 $e 20201103 $i 1878-8769 $m World neurosurgery $n World Neurosurg $x MED00167613
GRA    __
$a U54 GM104942 $p NIGMS NIH HHS $2 United States
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options